Capricor Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application for Deramiocel
PPMD is excited to learn that the FDA has accepted Capricor Therapeutics’ Biologics License Application (BLA) for review, seeking traditional approval for deramiocel (CAP-1002). Additionally, the FDA granted the BLA Priority Review, reducing the review…Learn More